Sun Pharmaceutical Industries Limited

NSEI:SUNPHARMA Stock Report

Market Cap: ₹4.4t

Sun Pharmaceutical Industries Management

Management criteria checks 4/4

We currently do not have sufficient information about the CEO.

Key information

Dilip Shanghvi

Chief executive officer

₹60.5m

Total compensation

CEO salary percentage75.6%
CEO tenure31.8yrs
CEO ownership9.6%
Management average tenure2.9yrs
Board average tenure3.6yrs

Recent management updates

This Is The Reason Why We Think Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) CEO Might Be Underpaid

Jul 30
This Is The Reason Why We Think Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) CEO Might Be Underpaid

Recent updates

Does Sun Pharmaceutical Industries (NSE:SUNPHARMA) Have A Healthy Balance Sheet?

Nov 18
Does Sun Pharmaceutical Industries (NSE:SUNPHARMA) Have A Healthy Balance Sheet?

Sun Pharmaceutical Industries Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

Oct 31
Sun Pharmaceutical Industries Limited Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year

We Ran A Stock Scan For Earnings Growth And Sun Pharmaceutical Industries (NSE:SUNPHARMA) Passed With Ease

Oct 21
We Ran A Stock Scan For Earnings Growth And Sun Pharmaceutical Industries (NSE:SUNPHARMA) Passed With Ease

Pinning Down Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) P/E Is Difficult Right Now

Aug 24
Pinning Down Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) P/E Is Difficult Right Now

Sun Pharmaceutical Industries Limited Just Beat EPS By 10%: Here's What Analysts Think Will Happen Next

Aug 06
Sun Pharmaceutical Industries Limited Just Beat EPS By 10%: Here's What Analysts Think Will Happen Next

This Is The Reason Why We Think Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) CEO Might Be Underpaid

Jul 30
This Is The Reason Why We Think Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) CEO Might Be Underpaid

Sun Pharmaceutical Industries (NSE:SUNPHARMA) Ticks All The Boxes When It Comes To Earnings Growth

Jun 30
Sun Pharmaceutical Industries (NSE:SUNPHARMA) Ticks All The Boxes When It Comes To Earnings Growth

Sun Pharmaceutical Industries (NSE:SUNPHARMA) Has A Rock Solid Balance Sheet

Jun 12
Sun Pharmaceutical Industries (NSE:SUNPHARMA) Has A Rock Solid Balance Sheet

Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Annual Results Just Came Out: Here's What Analysts Are Forecasting For This Year

May 25
Sun Pharmaceutical Industries Limited (NSE:SUNPHARMA) Annual Results Just Came Out: Here's What Analysts Are Forecasting For This Year

Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) Price Is Out Of Tune With Earnings

May 22
Sun Pharmaceutical Industries Limited's (NSE:SUNPHARMA) Price Is Out Of Tune With Earnings

Sun Pharmaceutical Industries (NSE:SUNPHARMA) Has A Rock Solid Balance Sheet

Mar 13
Sun Pharmaceutical Industries (NSE:SUNPHARMA) Has A Rock Solid Balance Sheet

Sun Pharmaceutical Industries' (NSE:SUNPHARMA) Upcoming Dividend Will Be Larger Than Last Year's

Feb 03
Sun Pharmaceutical Industries' (NSE:SUNPHARMA) Upcoming Dividend Will Be Larger Than Last Year's

Here's Why We Think Sun Pharmaceutical Industries (NSE:SUNPHARMA) Might Deserve Your Attention Today

Jan 05
Here's Why We Think Sun Pharmaceutical Industries (NSE:SUNPHARMA) Might Deserve Your Attention Today

CEO Compensation Analysis

How has Dilip Shanghvi's remuneration changed compared to Sun Pharmaceutical Industries's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

₹111b

Jun 30 2024n/an/a

₹104b

Mar 31 2024₹61m₹46m

₹96b

Dec 31 2023n/an/a

₹89b

Sep 30 2023n/an/a

₹85b

Jun 30 2023n/an/a

₹84b

Mar 31 2023₹55m₹41m

₹85b

Dec 31 2022n/an/a

₹42b

Sep 30 2022n/an/a

₹41b

Jun 30 2022n/an/a

₹39b

Mar 31 2022₹51m₹38m

₹33b

Dec 31 2021n/an/a

₹64b

Sep 30 2021n/an/a

₹62b

Jun 30 2021n/an/a

₹60b

Mar 31 2021₹46m₹35m

₹29b

Dec 31 2020n/an/a

₹24b

Sep 30 2020n/an/a

₹15b

Jun 30 2020n/an/a

₹7b

Mar 31 2020₹43m₹32m

₹38b

Dec 31 2019n/an/a

₹40b

Sep 30 2019n/an/a

₹43b

Jun 30 2019n/an/a

₹30b

Mar 31 2019₹263k₹1

₹27b

Dec 31 2018n/an/a

₹34b

Sep 30 2018n/an/a

₹24b

Jun 30 2018n/an/a

₹36b

Mar 31 2018₹34m₹28m

₹21b

Compensation vs Market: Dilip's total compensation ($USD708.95K) is below average for companies of similar size in the Indian market ($USD1.05M).

Compensation vs Earnings: Dilip's compensation has been consistent with company performance over the past year.


CEO

Dilip Shanghvi (69 yo)

31.8yrs

Tenure

₹60,541,920

Compensation

Mr. Dilip Shantilal Shanghvi serves as MD at Sun Petrochemicals Private Limited. He serves as Chairman of Board of Directors of Taro Pharmaceutical Industries Ltd at Taro Pharmaceuticals U.S.A., Inc. He se...


Leadership Team

NamePositionTenureCompensationOwnership
Dilip Shanghvi
MD & Chairman of the Boardno data₹60.54m9.6%
₹ 419.1b
Aalok Shanghvi
Executive VPno data₹68.75m0.12%
₹ 5.2b
C. Muralidharan
Chief Financial Officer7.5yrs₹38.89mno data
Davinder Singh
Executive Vice-President of Global Operationsno datano datano data
Dheeraj Sinha
EVP & Chief Information Officerless than a yearno datano data
Abhishek Sharma
VP, Head of Investor Relations & Strategic Projectsno datano datano data
Anoop Deshpande
Company Secretary & Compliance Officer2.9yrsno datano data
Kalyanasundaram Subramanian
Director of Corporate Developmentno data₹65.30mno data
Suresh Rai
Chief Human Resources Officerless than a yearno datano data
Kirti Ganorkar
Head of India Businessno datano datano data
Abhay Gandhi
Chief Executive Officer of North America Business8.3yrsno datano data
Azadar Hussain Asghar Khan
Head of Corporate Relations & CSR - India Regulatory Affairsno datano datano data

2.9yrs

Average Tenure

60yo

Average Age

Experienced Management: SUNPHARMA's management team is considered experienced (2.9 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Dilip Shanghvi
MD & Chairman of the Board31.8yrs₹60.54m9.6%
₹ 419.1b
Aalok Shanghvi
Executive VP1.5yrs₹68.75m0.12%
₹ 5.2b
Sudhir Valia
Non-Executive & Non-Independent Director30.9yrs₹2.20m1.8%
₹ 78.5b
Rama Bijapurkar
Non-Executive & Independent Director3.6yrs₹5.10mno data
Gautam Doshi
Non-Executive Independent Director6.6yrs₹7.80mno data
Rolf Hoffmann
Independent Director1.5yrs₹3.20mno data
Pawan Goenka
Lead Independent Director3.6yrs₹8.50mno data
Sanjay Asher
Independent Director2.1yrs₹4.80mno data

3.6yrs

Average Tenure

67.5yo

Average Age

Experienced Board: SUNPHARMA's board of directors are considered experienced (3.6 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/25 19:54
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2024/03/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Sun Pharmaceutical Industries Limited is covered by 73 analysts. 36 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Nitin BhasinAmbit Capital
Prashant NairAmbit Capital
null nullAnand Rathi Shares and Stock Brokers Limited